Recon: Novartis to buy Tourmaline for $1.4B; Trump could offer carve-outs for pharma in future trade pacts

• Vaccine policy threatens to put Kennedy at odds with Trump (STAT)
• Trump may exempt some pharma products from tariffs in future trade deals (Endpoints)
• Regeneron patent deal with Sandoz clears path for new Eylea biosimilar launch in 2026 (Endpoints)
• New FDA approval pathway for n-of-1 therapies coming soon, Prasad says (Endpoints)
• US Hasn’t Started Writing Autism Report, FDA Leader Says (Bloomberg)
• Internal Mock DEA-Style and Mirror Inspections and Audits: Trust But Verify (FDA Law Blog)
• MAHA report on US children's health targets food and drug marketing (Reuters)

• US FDA deems Sun Pharma's Halol plant not compliant with its manufacturing rules (Reuters)
• EU Critical Medicines Act: Parliament Clarifies ‘Significant Proportion’ Rule (Pink Sheet)
• UK To Formalize ‘Research As Care’ Concept To Boost Clinical Trial Participation (Pink Sheet)
• Switzerland’s swissdamed UDI Goes Live Ahead Of 2026 Mandatory Compliance (MedTech Insight)
• Without A Delayed EU AI Act Application, Medtech Could Be Derailed Again (MedTech Insight)

• Pricing group says weight-loss drugs becoming more cost-effective (Reuters) (STAT)
• Novartis to buy Tourmaline Bio, gaining promising heart medicine (STAT)
• Lilly's blood cancer drug shows promise in trial as early treatment (Reuters)
• Lilly will let small biotechs use its AI models at no cost (STAT) (Reuters)
• Ideaya touts trio of cancer drugs as it eyes spot in precision oncology market (Endpoints)
• Regeneron’s promising antibody for cat, birch allergies; Ascletis targets quarterly GLP-1 shot (Endpoints)
• Bertozzi-advised Ridge Bio lands $25M to help drugmakers come up with better ADCs (Endpoints)
• Summit plays defense for the first time as questions loom over Phase 3 lung cancer readouts (Endpoints)
• Pfizer reports new Covid-19 vaccine data after defending the product (Endpoints)

• Previous CT scans may increase pregnancy risks (Reuters)
• Pulse wins IDE approval; Galvanize pulls in $100M (MedTech Dive)
• Microbot receives 510(k) clearance for endovascular robot (MedTech Dive)
• Investors Want Proof of Big Tech’s AI Progress (Bloomberg)

• Salmonella linked to home-delivery meals sold in 10 states: CDC (The Hill)
• Campbell’s company says it will stop using artificial food dyes (Food Safety News)

• Bringing AI to medicine requires philosophers, cognitive scientists, and ethicists (STAT)
• Epic must face claims it used monopoly power to harm a rival business, judge rules (STAT)
• Former top FDA digital leader lands at Mayo Clinic (STAT)
• What states will be next to end school vaccine requirements? (STAT)
• UnitedHealth sees 78% of members in high-rated Medicare plans (Reuters)
• FCA Enforcement Shows No Signs of Slowing, Attorney Tells Medtech Companies (MedTech Insight)
• Doctors group recommends COVID-19 vaccine for all adults in break with government (The Hill)